Shots:
- BioArctic has entered into an option, collaboration, and license agreement with Novartis to develop a neurodegeneration treatment using BrainTransporter
- As per the deal, BioArctic receives $30M upfront and could earn up to $772M in milestones plus tiered mid-single-digit royalties if Novartis licenses and commercializes the drug
- BioArctic will develop a drug candidate using BrainTransporter and a Novartis antibody; if Novartis exercises its option, it will take over global development and commercialization. BioArctic retains BrainTransporter rights outside this deal, enabling future partnerships across various therapeutic areas
Ref: BioArctic | Image: Novartis & BioArctic | Press Release
Related News:- Eisai, Biogen and BioArctic Report the EC’s Approval of Leqembi (lecanemab) for Early Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
